相关实验视频

Updated: Jul 4, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

伦瓦提尼布加剧了肝细胞癌患者的骨肌肉量减少,而阿特佐利祖马布加贝瓦西祖马布没有

Kenji Imai¹, Koji Takai¹, Shinji Unome¹

¹Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.

|January 26, 2024

概括

在肝细胞癌 (HCC) 患者中,阿特佐利祖马布加贝瓦齐祖马布 (AB) 维持了骨肌肉指数 (SMI),而不是伦瓦丁尼布 (LEN). 保持SMI对于生存至关重要,使得AB在HCC治疗期间保持肌肉健康的优势.

科学领域:

肝细胞癌研究肝细胞癌研究
瘤学治疗学治疗学
身体组成分析身体成分分析

背景情况:

肝细胞癌 (HCC) 治疗影响患者的身体组成和生物标志物.
骨肌肉指数 (SMI) 是癌症患者潜在的预后因素.
了解脂肪组织和瘤标志物的与治疗相关的变化至关重要.

研究的目的:

为了评估SMI的时间变化,脂肪组织指数 (SATI,VATI),AFP,PIVKA-II和ALBI分数在HCC治疗阿特佐利祖马布加贝瓦齐祖马布 (AB) 或伦瓦提尼布 (LEN) 期间进行评估.
确定这些变化对患者存活时间的影响.
确定治疗期间生存和SMI变化的预测因素.

主要方法:

对94名HCC患者 (37名在AB,57名在LEN) 的分析,在治疗开始,3个月,治疗结束和最后一次观察时进行测量.
使用威尔科克森配对测试进行时间变化分析.
采用Cox比例危险模型和协差分析,以确定生存和SMI变化的独立预测因素.

主要成果:

在接受AB治疗时,SMI保持不变,但在接受LEN治疗时显著下降.
SMI,AFP和ALBI分数是生存的独立预测指标.
药物选择 (AB与LEN) 和PIVKA-II是SMI变化的独立预测因素.

结论:

在肝细胞癌 (HCC) 治疗期间,阿特佐利祖马布加贝瓦齐祖马布 (AB) 在维持骨肌肉指数 (SMI) 方面优于伦瓦丁尼布 (LEN).
维持SMI是改善HCC患者生存结果的关键因素.
在HCC治疗期间,应监测身体成分变化和特定生物标志物.

关键词:

它们是Atezolizumab.这是bevacizumab的治疗方法.肝细胞癌是肝细胞癌.伦瓦提尼布 (Lenvatinib) 是一种药物.预后因素是一个预后因素.这种类型的麻症是sarcopenia.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.